

Foundation Inspire2Live

Annual Report 2022

This report has been approved by the Supervisory Board on March $8^{\text{th}},\,2023$

Version: March 8th, 2023

We are the patient's voice in cancer!



Supervisory board report

In 2022 the world started to recover from the effects that the COVID-pandemic had on economies, social structures and personal lives. For Inspire2Live it meant that as a result of loosening travel restrictions, on-line interactions could be complemented with in-person gatherings, which deepened the mutual relationships.

The World Campus of Inspire2Live grew to more than 80 Patient Advocates and Scholar Activists in more than 40 countries and initiated numerous working groups around initiatives that will contribute to the worldwide battle against cancer.

Inspire2Live is developing towards an organisation that is able to take on ambitious and extensive projects like early detection of cancer or patient centric cancer treatment. To that end, Inspire2Live transformed in 2022 its subsidiary Inspire2Go into SanInfo, a project-organisation able to execute those kinds of projects.

Further professionalization and growth will be needed to meet the challenges of running complex projects next to an international network organisation. In 2022 the Supervisory Board responded to this by recruiting two new members who bring relevant experience and capabilities to the table, which will help to guide and support the growth and professionalization trajectories. In February 2023, the Supervisory Board also appointed two new members of the Executive Board, thus securing continuity, complementarity in capabilities and sufficient capacity to steer the organisation.

The most pressing challenge for realising our ambitions still lies in securing financial support for our projects and for the organisation of Inspire2Live. In 2022 we started to gain experience with applications for grants and subsidies. In 2023 we will continue our quest to secure funding.

We thank all Patient Advocates and Scholar Activists for their endless energy and drive they devote to our battle against cancer.

Here the bios and photos of the members of the supervisory board.

Amsterdam, March 8th, 2023

Sylvia Butzke

Chairman of the Supervisory Board

We are the patient's voice in cancer!



Executive board report

This board report contains information about our financial year 2022.

In 2022 Inspire2Live had only one board member. We thought it was better to broaden the board and now, since February 15th, 2023, Inspire2Live has an executive board, which is formed by Ilona Schelle, Peter Kapitein and Tielo Jongmans. This board manages the daily operations.

Inspire2Live is a not-for-profit organisation that relies heavenly upon donations. Read <u>here</u> about some of our donations and spending.

Here the bios and photos of the members of the <u>executive board</u>, as well as the members of <u>supportive teams</u>.

Our patient advocates and scholar activists

Our organisation now consists of more than 80 active patient advocates in more than 40 countries. We are still expanding. Of course, this is mainly a result of our World Campus activities which we will address later in the report.

Meet our patient advocates and scholar activists

Our patient advocates and scholar activists are highly educated, well informed and very eloquent. In their work they combine emotion (as a driving force) with their background based on science, knowledge and facts. They are visible in dozens of initiatives, give dozens of talks and write dozens of blogs, articles and books. Our Patient Advocates are themselves cancer patients, or have experienced the devastation of personal and family life that is caused by cancer. They have felt the anguish and the suffering. We take cancer personally.

Inspire2Live is highly recognized in initiatives around personalized medicine, setting up innovative research for better treatments, concentration of cancer care in excellent cancer centres, better diagnosis, food and cancer, prevention (among this is tobacco), the affordability and access to drugs, the design of trials, influencing government and industry... We know what we are talking about. Some of these topics are being discussed in parliament. Through lobbying we find effective and efficient access to the members of parliament in The Hague and Brussels... We know how to influence.

Through our activities in the World Campus, we work towards a strategic alliance with the International Agency of Research on Cancer of the World Health Organisation (IARC). We know how to cooperate and already have an intense relationship with WHO/IARC.

We are the patient's voice in cancer!



Meetings

Due to both COVID19 and the World Campus, we had, just as in 2020 and 2021, lots of online meetings and of course these meetings were international.

The regular <u>World Campus Meeting</u> every last Wednesday of the month at 3 pm CET with all our patient advocates is a huge success and very well visited. The structure is:

- Start with a short introduction of the new patient advocates
- A lecture by a guest speaker or by one of our patients advocates
- Followed by an extended discussion on this topic
- Updates from the working groups

Our working groups

Out of the 'Last Wednesday of the month' meetings arise ideas and initiatives. We see that the flow 'idea - initiative – project – going concern' has now been established in Inspire2Live and her company SanInfo.

When our advocates think that an idea is fruitful and can add value to our mission, a working group is started. We now have the following working groups:

- Book project (in this the former topic 'Mobilizing Knowledge')
- Breast Cancer
- Cancer as the new pandemic
- Data
- Early detection
- HPV-related cancer
- Lifestyle and cancer
- Pain
- Personalized Medicine
- Registries
- Tobacco

Public Relations

Our Communication Team meets up once a month to discuss current and future projects.

At least once a week we publish a new article on our website and promote it on our social media channels (Facebook, Instagram, LinkedIn, Twitter). Each time a patient advocate joins our organisation we publish their bio on our website. We also add them to our MS Teams environment.

Our MS Office 365 environment is donated for free by Microsoft and is maintained by our Communication Team. We are thankful for the free support of <u>DTX</u>, a small organisation who kindly assist us in technical Microsoft365 matters.

Our new website went live in May 2022. In the background we are continuously working on improving our content and technical functionality. Recently we have also added our ambassadors to

We are the patient's voice in cancer!



the website and we have updated the Lectures and Sessions section to reflect its content in a better way.

Our patient advocates and scholar activists have published in many journals and newspapers this year. We share as much as possible. We also have a partnership with Health Management Journal, an international journal with topics related to many health issues.

During our annual congress the Communication Team worked together with a great group of people for maximum exposure on our website and social media channels. A lot of preparation time went into this. After the congress all talks and presentations have been published on our website. Additional video material is available and will be used for promotion. We thank all our partners for supporting us during the congress.

Our achievements

Inspire2Live was founded in 2010 and started immediately after the Annual congress of 2011 with her activities. We are very proud of the many things we have achieved.

We started initiatives for organoids, in the Netherlands we created for cancer patients the possibility to have their Whole Genome Sequenced through a unanimous majority in the Dutch Parliament (it works as an example and catalyst for other countries).

What about starting the World Campus; a network of more than 80 patient advocates and scholar activists in more than 40 countries working together to fight cancer and cooperate based on reciprocity. The principles of the Red Cross have been implemented by Inspire2Live. Political, religious, historical or cultural differences are not allowed to stand in the way of cooperation. In this network researchers from Iran work with researchers from Israel. Turkey is facilitating Armenia. The World Campus as a global advocacy group for cancer has no precedent.

Many more has been achieved and you find them on our website.

Our Projects

Inspire2Live has many working groups as described above. Out of these activities come a lot of projects. Our advocates work intensely on this with the aim to improve the quality of life of cancer patients and their loved ones globally.

We are the patient's voice in cancer!



We started a registry for cancer in Armenia! And we have designed a project that is the first of its kind as a real patient centric approach for treating patients: DEEP Diagnostics (for this patient, with her defect, at this moment, we need this treatment). Away from drug centric and now real Personalized Medicine.

We have built a close relation and cooperation with <u>SeekIn</u>, the Chinese company of our own patient advocate <u>Mao Mao</u>. We (Inspire2Live and SeekIn) have products on the shelf, not only in research, that detect cancer in its earliest stage and can determine after 1 cycle whether a treatment works or not. These are unique products that we bring to all the people in the world. This is real '*Bottom-up cancer support*.'

Many more projects have been started and you find them on our website.

Statement from the Finance Manager

You will find our financial position at the end of this document.

In Memoriam

Léonie Sazias.

In 2022 we lost our strong and powerful advocate Léonie Sazias. She died of metastasized colon cancer and was a decisive power in our successful attempt in the Dutch parliament to realize molecular diagnostics. She embodied our slogan: 'Sequence me!'

Please read her in memoriam.

Amsterdam, March 8th, 2023

Foundation Inspire2Live Ilona Schelle, Peter Kapitein & Tielo Jongmans

> We are the patient's voice in cancer! If about us, not without us • www.inspire2live.org



Financial Report 2022

Balance sheet as at 31 December 2022

		2022	2021
		EUR	EUR
Fixed assets			
Participations	1	1	1
Long-term receivables	2	10,000	<u>10,000</u>
Total fixed assets		10,001	10,001
Current assets			
Receivables	3	99	5,946
Cash and cash equivalents	4	<u>62,832</u>	<u>187,674</u>
Total current assets		72,932	203,621
		<u>203,620</u>	<u>292,943</u>
Foundation's equity	5	20,697	184,403
Current liabilities	6	<u>52,235</u>	<u>19,218</u>
		72,932	<u>203,621</u>

We are the patient's voice in cancer! If about us, not without us • www.inspire2live.org



Statement of income and expenses for the year ended 31 December 2022

		2022	2021
		EUR	EUR
Income	7	879	6,800
Operating costs	8	<u>164,585</u>	<u>114,892</u>
Result		-/- 163,706	-/- 108,541
Share in result of group companies		<u>0</u>	1
Total result		-/- 163,706	-/- 108,540

Notes to the financial statements for the year 2021

General

Applied standards

The financial statements were prepared in accordance with good merchant use and the provisions of Part 9, Book 2, of the Netherlands Civil Code. Inspire2Live however uses its own principles for valuation and determination of results, as allowed by Dutch law. These principles, however, largely correspond to the Guidelines for Annual Reporting for small organisations with no profit motive (RJ(k)-C1).

Activities

The principal goals of Inspire2Live are:

- stimulating organisations that aim to organize events for cancer research
- setting up global collaboration to achieve medical research in a sustainable manner
- promoting and supporting scientific research into cancer in all possible forms, so that people can live a happy, healthy life in harmony with cancer and getting cancer under control
- to profile her behaviour both internally and externally as a non-governmental organisation ("NGO") and in the performance of her duties
- maintain independence

We are the patient's voice in cancer!



The foundation intends to achieve its goal by, among other things:

- promoting patient advocacy and supporting research;
- the development of activities that contribute directly or indirectly to the achievement of its objective, including ancillary commercial and profitable activities within the limits of what is legal permitted and the proceeds of which will become available at any time and are intended for achieving the objective.

Principles for the valuation of assets and liabilities and the determination of the results

General

If not stated otherwise, assets and liabilities are shown at nominal value. An asset is disclosed in the balance sheet when it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the cost of the asset can be reliably measured. A liability is disclosed in the balance sheet when it is expected to result in an outflow from the entity of resources embodying economic benefits and the amount of the obligation can be measured with sufficient reliability.

If a transaction results in a transfer of future economic benefits and or when all risks relating to assets or liabilities transfer to a third party, the asset or liability is no longer included in the balance sheet. Assets and liabilities are not included in the balance sheet if economic benefits are not probable or cannot be measured with sufficient reliability.

The income and expenses are accounted for in the period to which they relate.

The preparation of the financial statements requires the board to form opinions and to make estimates and assumptions that influence the application of principles and the reported values of assets and liabilities and of income and expenditure. The actual results may differ from these estimates. The estimates and the underlying assumptions are constantly assessed. Revisions of estimates are recognized in the period in which the estimate is revised and in future periods for which the revision has consequences.

Receivables

Receivables are stated at nominal value less a provision for doubtful debts. Provisions are designated on the basis of individual assessment of recoverability of the receivable.

<u>Result</u>

The result is calculated as the difference between income and all the costs attributable to it during the year under review. The costs are calculated with due regard for the applicable valuation principles stated previously.

We are the patient's voice in cancer!



Balance sheet as at 31 December 2021

Financial fixed assets

1. Participations	2022	2021
	EUR	EUR
Participation SanInfo B.V.	1	1

2. Long term receivables	2022	2021
	EUR	EUR
Loan SanInfo B.V.	10,000	10,000

In 2020 Inspire2Live financed the start-up capital of Inspire2Go BV. Inspire2Go's main objective is to provide care projects and tasks commercially, with the proceeds ultimately benefiting causes such as Inspire2Live. The loan of € 10,000 can be seen as risk-bearing capital. For the time being, no interest is due on the outstanding balance. Inspire2Go has been succeeded by Saninfo, and all its assets and obligations are now part of SanInfo, which is a wholly owned subsidiary of Inspire2Live.

Current assets

3. Receivables	2022	2021
	EUR	EUR
Current account SanInfo B.V.	99	99
Accruals	0	5,847
31 December	<u>99</u>	<u>5,946</u>

4. Cash and cash equivalents	2022	2021
	EUR	EUR
Rabobank 1356.22.883	12,832	67,661
Rabobank savings account	<u>50,000</u>	<u>120,012</u>
31 December	<u>62,832</u>	<u>187,673</u>

We are the patient's voice in cancer!



5. Foundation's equity	2022	2021
	EUR	EUR
Balance as at 1 January	184,40	292,943
Result for the year	<u>-/- 163,706</u>	<u>-/- 108,540</u>
31 December	<u>20,697</u>	<u>184,403</u>

6. Current liabilities	2022	2021
	EUR	EUR
Creditors	52,214	19,018
Other liabilities	21	200
31 December	<u>52,235</u>	<u>19,218</u>

Statement of income and expenses for the year ended 31 December 2022

7. Income	2022	2021
	EUR	EUR
Total	<u>879</u>	<u>6,800</u>

During the 2022 financial year, the average number of employees, converted into full-time equivalents on the payroll of the foundation, amounted to nil persons (2021: nil persons).

The board of Foundation Inspire2Live does not receive any remuneration and is independent of any scientific or fundraising organisation from which the foundation receives subsidy or other grants. De Nederlandsche Bank allows Peter Kapitein to work three days a week for the foundation.



8. Operating costs	2022	2021
	EUR	EUR
Volunteer allowances	0	1,800
General costs	49,999	51.646
Project costs	114,000	61.894
Financial costs	<u>586</u>	449
	<u>164,585</u>	<u>115.340</u>

9. General costs	2022	2021
	EUR	EUR
Travel costs for connection	7,599	3.741
Costs Inspire2Go	167	718
External hiring	10,000	10,000
Various costs	<u>0</u>	37.187
	<u>49,999</u>	<u>51.646</u>

The travel costs for connection consist of travel expenses in Europe and the USA for visiting several congresses and people.

10. Project costs	2022	2021
4	EUR	EUR
Annual congress	79,013	15,443
May Assembly	29,987	0
Script for Movies HPV Related Cancers Nigeria	0	4,740
Congress Lifestyle and Cancer	0	512
Congress Moving evidence into practice	0	2,885
Congress World Campus	0	8,436

We are the patient's voice in cancer!



Project Hubs	0	0
Project Lead World Campus	5,000	10,000
Project Lead Pain Management	0	5,00
Trial Lidopan	0	14,114
Project others	<u>0</u>	<u>764</u>
	<u>114,000</u>	<u>61,894</u>

Operating costs include VAT, which cannot be refunded by Foundation Inspire2Live.

Inspire2Live agreed that charges for temporary staff will not exceed EUR 80 per hour.

Amsterdam, March 8th, 2023

Foundation Inspire2Live

Ilona Schelle, Peter Kapitein & Tielo Jongmans